Search Results
Your search for A matches 32881 pages
Showing 17051 - 17100AMA Rejects Recommendation to Reaffirm Opposition to Medical Aid in Dying
On June 11, the American Medical Association (AMA) House of Delegates voted 56% to 44% to reject a report by its Council on Ethical and Judicial Affairs (CEJA) that recommended the AMA maintain its Code of Medical Ethics’ opposition to medical aid in dying. Instead, the House of Delegates...
Male Thyroid Cancer Survivors Face 50% Higher Risk of Cardiovascular Disease Than Women
Male thyroid cancer survivors have a nearly 50% higher risk of developing cardiovascular disease than women within 5 years of cancer diagnosis, according to a new study published by Park et al in the Journal of Clinical Endocrinology & Metabolism. More than 62,000 new cases of thyroid cancer...
Low-Fat Dietary Intervention and Overall Survival After Breast Cancer Diagnosis
In an analysis from the Women’s Health Initiative (WHI) trial reported in JAMA Oncology, Chlebowski et al found that overall survival after the diagnosis of incident breast cancer was improved in women in the reduced-fat dietary intervention group vs control group, reflecting reduced...
Prophylactic Cranial Irradiation in Stage III NSCLC
In a Dutch phase III trial reported in the Journal of Clinical Oncology, De Ruysscher et al found that prophylactic cranial irradiation (PCI) prevented symptomatic brain metastases vs observation in patients with stage III non–small cell lung cancer (NSCLC) receiving treatment with curative...
FDA and EMA Accept Regulatory Submissions for Review of Talazoparib for Patients With Germline BRCA-Mutated Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) recently accepted for filing and granted Priority Review designation a new drug application for talazoparib. The submission is based on results from the EMBRACA trial, which evaluated talazoparib vs chemotherapy in patients with germline BRCA-mutated,...
Eating a High-Quality Diet Could Decrease Cancer Survivors’ Risk of Death by 65%
Cancer survivors who consumed a balanced, nutrient-dense diet had a 65% lower risk of dying from cancer than survivors who ate a poor-quality diet, according to findings published by Deshmukh et al in JNCI Cancer Spectrum. The study suggests that more than focusing on any particular food group,...
ASCO Guideline for Geriatric Oncology: Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy
As reported in the Journal of Clinical Oncology by Supriya G. Mohile, MD, of the University of Rochester Medical Center, and colleagues, ASCO has produced a guideline on the practical assessment and management of vulnerabilities in geriatric patients receiving chemotherapy. To develop the...
Total Neoadjuvant Therapy for Borderline Resectable Pancreatic Adenocarcinoma
In a single-institution phase II trial reported in JAMA Oncology, Murphy et al found that total neoadjuvant therapy with FOLFIRINOX (fluorouracil [5-FU], irinotecan, and oxaliplatin) and individualized chemoradiotherapy was associated with a high R0 resection rate and good outcomes in patients with ...
Study Finds Recent-Onset Type 2 Diabetes May Be Early Manifestation of Pancreatic Cancer
According to the American Cancer Society, pancreatic cancer is one of the most deadly cancers, with an overall 5-year survival rate of just 8%, mainly because the vast majority of patients, about 80%, are diagnosed at a late stage of disease. Research has shown that identification of high-risk ...
Studies of Daratumumab in Combination With Anti–PD-L1 Agents Stopped
On May 26, Genmab A/S announced that following a planned review, the Data Monitoring Committee (DMC) has recommended that the phase Ib/II study (CALLISTO/LUC2001) of daratumumab (Darzalex) in combination with the anti–programmed cell death ligand 1 (PD-L1) antibody atezolizumab (Tecentriq) vs ...
AMA Releases New Physician Guide on Caring for the Caregiver
Every day in their treatment rooms, physicians encounter individuals who are making profound sacrifices to help a loved one who is seriously ill, often at the expense of their own well-being. To help physicians understand the day-to-day challenges and risk of burnout faced by informal caregivers,...
Study Finds Breast Cancer Survivors Are Not Getting Recommended Number of Mammograms Postsurgery
Breast cancer survivors are not getting the recommended level of screening postsurgery, according to a study by Ruddy et al in JNCCN–Journal of the National Comprehensive Cancer Network. The study was led by Kathryn Ruddy, MD, MPH, Director of Cancer Survivorship for the Department of...
Opportunities, Issues, and Challenges for Biosimilars in Oncology
In an article in The New England Journal of Medicine, Lyman et al reviewed opportunities, issues, and challenges posed by the advent of biosimilar medications, focusing on biosimilars in cancer treatment. Although these agents could help to meet the health-care goals of high quality care with cost...
Lung Cancer Incidence in Young Women vs Men in the United States
In a study reported in The New England Journal of Medicine, Jemal et al found that the incidence of lung cancer in young white and Hispanic women is now higher than that in men in the US. Study Details The study involved analysis of data from the North American Association of Central Cancer...
Characteristics and Screening of Brain Metastases in Breast Cancer and NSCLC
In a research letter published in JAMA Oncology, Cagney et al found that brain metastases were more advanced and more likely to be symptomatic in patients with breast cancer compared to patients with non–small cell lung cancer (NSCLC). Current guidelines recommend magnetic resonance imaging...
FDA Expands Approval of Pembrolizumab to Include New Lymphoma Indication
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma or those who have relapsed after two or more prior lines of therapy. KEYNOTE-170...
FDA Approves Bevacizumab Plus Chemotherapy in Advanced Ovarian Cancer Following Initial Surgery
Today, the U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin) in combination with chemotherapy (carboplatin and paclitaxel) followed by bevacizumab as a single agent for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection....
Barbara L. McAneny, MD, Inaugurated as 173rd President of the AMA
Barbara L. McAneny, MD, an oncologist from Albuquerque, has been sworn in as the 173rd President of the American Medical Association (AMA). She will focus her tenure on the AMA’s three strategic arcs: attacking the dysfunction in health care by removing obstacles and barriers that interfere...
ESMO Emphasizes Importance of Cancer on the Global Health Agenda at the 71st World Health Assembly
At the 71st World Health Assembly in Geneva, the European Society for Medical Oncology (ESMO) delivered two statements positioning cancer as a priority on the global agenda of the World Health Organization (WHO). Presenting its recommendations for action to the international community,...
iLLUMINATE Trial of Ibrutinib Plus Obinutuzumab for First-Line Therapy of CLL/SLL Meets Primary Endpoint
The phase III iLLUMINATE (PCYC-1130) trial recently met its primary endpoint of improvement in progression-free survival. The study evaluated ibrutinib (Imbruvica) in combination with obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia or small lymphocytic...
ASCO Clinical Practice Guideline Focused Update: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer
As reported by Neelima Denduluri, MD, of US Oncology Network, Virginia Cancer Specialists, and colleagues in the Journal of Clinical Oncology, ASCO has issued a focused update on the clinical practice guideline on optimal chemotherapy and targeted therapy in early breast cancer. To develop the...
Analysis of Intracranial Response to Brigatinib in ALK-Positive NSCLC With Brain Metastases
In an analysis of two clinical trials reported in the Journal of Clinical Oncology, Camidge et al found that brigatinib (Alunbrig) produced high intracranial response rates and good intracranial progression-free survival in patients with ALK-positive non–small cell lung cancer (NSCLC) and...
Automated Bone Scan Index and Overall Survival in Metastatic Castration-Resistant Prostate Cancer
In a secondary analysis of the phase III 10TASQ10 trial comparing tasquinimod vs placebo in chemotherapy-naive metastatic castration-resistant prostate cancer, the automated Bone Scan Index (aBSI) was shown to be predictive of overall survival. The findings were reported in JAMA Oncology by...
FDA Approves Pembrolizumab for Previously Treated Recurrent or Metastatic PD-L1–Expressing Cervical Cancer
On June 12, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the treatment of patients with recurrent or metastatic cervical cancer and disease progression on or after chemotherapy whose tumors express programmed cell death ligand 1 (PD-L1) [Combined Positive Score...
Older Patients With Melanoma Fare Better on Anti–PD-1 Immunotherapy Than Younger Patients
Recent research has shown that the tumor microenvironment in older patients promoted melanoma metastasis and resistance to targeted therapy with a BRAF inhibitor. Now, a new study investigating the relationships among age, response to anti–programmed cell death protein 1 (PD-1)...
Cancer Prevention Report Shows Consensus Among Global Experts on 10 Steps to Reduce Risk
An internationally released comprehensive analysis of research on lifestyle factors and cancer prevention confirms the critical links between cancer diagnoses and diet, physical activity, and weight. Independent experts from across the globe reviewed decades of scientific evidence to develop the...
AUA 2018: Finasteride Reduces Risk of Prostate Cancer and Is Safe, Long-Term Results Show
Twenty-five years after it opened for enrollment, the Prostate Cancer Prevention Trial (PCPT) has delivered a final verdict: finasteride, a common hormone-blocking drug, reduces men's risk of getting prostate cancer without increasing their risk of dying from the disease. Initial study...
Surveillance Intensity Not Associated With Earlier Detection of Recurrence or Improved Survival in Patients With Colorectal Cancer
A national retrospective study led by researchers at The University of Texas MD Anderson Cancer Center found no association between intensity of posttreatment surveillance and detection of recurrence or overall survival (OS) in patients with stage I, II, or III colorectal cancer. Published by...
Rivaroxaban vs Dalteparin in Patients With Venous Thromboembolism
In a UK pilot trial (SELECT-D) reported in the Journal of Clinical Oncology, Young et al found that the oral factor Xa inhibitor rivaroxaban was associated with a lower rate of recurrent venous thromboembolism (VTE) but a higher rate of clinically relevant nonmajor bleeding compared with the...
Risk-Adapted Treatment for Young Children With Medulloblastoma
In a phase II trial (SJYC07) reported in The Lancet Oncology, Robinson et al found that risk-adapted treatment did not improve event-free survival in young children with medulloblastoma. Analysis by methylation status showed superior outcome in the sonic hedgehog (SHH) subgroup. Study Details The ...
Rapid Progression of Adult T-Cell Leukemia/Lymphoma During PD-1 Inhibitor Therapy
In a letter to the editor in The New England Journal of Medicine, Ratner et al describe rapid progression of adult T-cell leukemia/lymphoma (ATLL) in three consecutive patients receiving programmed cell death protein 1 (PD-1) inhibitor therapy with nivolumab (Opdivo). As stated by the authors,...
ASCO’s TAPUR Study Website Now Features Updates on Patient Cohort Expansions and Closures
ASCO’S TARGETED Agent and Profiling Utilization Registry (TAPUR) Study now provides a full list of patient cohort expansions and closures on its website. Based on treatment responses in stage I, patient cohorts are either expanded to stage II for further study and identification of a signal or...
John V. Cox Reflects on 10 Years as Editor-in-Chief of the Journal of Oncology Practice
John V. Cox, DO, FASCO, of the Parkland Hospital and Health System/University of Texas Southwestern Medical Center, has served as the Editor-in-Chief of the Journal of Oncology Practice (JOP) since 2008. As a member of the journal’s inaugural Editorial Board, he has seen the publication evolve...
Share ASCO Answers Fact Sheets With Your Patients
DIRECT, EASY to understand, and in a convenient single-page format, ASCO Answers fact sheets introduce patients and their caregivers to types of cancer and cancer-related topics, including treatments and side effects. Each fact sheet includes an overview of the topic, methods for management and...
Spotlight on Women Who Conquer Cancer
WOMEN WHO CONQUER CANCER is a group dedicated to advancing cancer research by supporting young women researchers early in their careers through Conquer Cancer Foundation of ASCO Young Investigator Awards (YIAs). These 1-year grants give promising researchers the boost they need to get started on...
Resources to Help You Understand What Right-to-Try Legislation Means for Practices, Patients
WITH CONGRESS having recently passed federal “right-to-try” (RTT) legislation, ASCO has developed a suite of educational resources that will help members understand the impact of this law on cancer care and individuals with cancer. Educational resources include: Podcast THE LATEST ASCO in Action...
ASCO to Present Douglas W. Blayney, MD, FASCO, With Joseph V. Simone Award and Lecture
ASCO will recognize Douglas W. Blayney, MD, FASCO, medical oncologist and Professor at Stanford University School of Medicine, with the Joseph V. Simone Award and Lecture for Excellence in Quality and Safety in the Care of Patients with Cancer. Dr. Blayney will be presented with the award at the...
ASTRO Collaborates With ASCO and Conquer Cancer to Support Methods Workshop
For the third year, the American Society for Radiation Oncology (ASTRO) is supporting the ASCO/American Association for Cancer Research (AACR) Workshop on Methods in Clinical Cancer Research, to take place July 18–August 3, 2018, at Vail Mountain Marriott Resort in Vail, Colorado. Celebrating its ...
Expert Point of View: John V. Heymach, MD, PhD
FORMAL DISCUSSANT of this trial, John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, also was optimistic about these early findings. “This is a proof-of-concept study showing this approach is safe. Only modest activity was observed with standard [Response...
Early Evidence of Neoadjuvant PD-1 Blockade in Non–Small Cell Lung Cancer
A NOVEL APPROACH using two doses of nivolumab (Opdivo) prior to surgery achieved major pathologic responses in 45% of patients with resectable stages I to IIIA non–small cell lung cancer (NSCLC), according to the results of a small Stand Up 2 Cancer–Cancer Research Institute Dream Team study...
Study Evaluates Effect of Restrictive Opioid Protocol After Gynecologic Surgery
THE NUMBER of opioids prescribed after surgery for gynecologic cancer decreased significantly after implementation of an ultra-restrictive opioid prescription protocol, with no apparent negative effect on patient satisfaction or pain, according to research presented by Jaron Mark, MD, and...
Expert Point of View: Shitanshu Uppal, MD
COMMENTING ON the study, invited discussant Shitanshu Uppal, MD, of the University of Michigan in Ann Arbor, called the data “provocative” but said he had progressed through the “five stages of grief” in reaction to the results. “I’ve gone through denial, I’ve gone through anger, I couldn’t...
Poorer Outcomes Reported With Minimally Invasive Surgery Than Open Approach in Early Cervical Cancer
PATIENTS UNDERGOING minimally invasive radical hysterectomy for early cervical cancer had higher rates of disease recurrence and worse disease-free, progression-free, and overall survival than did women who had the open approach, according to results from the phase III LACC trial, presented by...
Clinical Findings Predict Early Treatment Discontinuation in Patients Receiving Immunotherapy for Ovarian Cancer
PRETREATMENT CLINICAL findings may predict early treatment discontinuation in patients with ovarian cancer receiving checkpoint blockade immunotherapy agents. Data presented by MD candidate Julia L. Boland at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer revealed that...
Quick Takes From Original Research Presented at the 2018 NCCN Annual Conference
THE QUANTITY of original research presented at the National Comprehensive Cancer Network® (NCCN®) Annual Conference has been growing, and at the 2018 meeting, 121 researchers presented their work. The ASCO Post captured some of the findings for this report. Blood Markers Correlate With Anti–PD-1...
Using Neoadjuvant Therapy to Reduce Early Recurrences, Increase Survival in Patients With Pancreatic Cancer
USE OF THE FOLFIRINOX regimen (fluorouracil, leucovorin, irinotecan, and oxaliplatin) was associated with a 4.9-month improvement in overall survival compared to gemcitabine/ nab-paclitaxel (Abraxane) in the neoadjuvant treatment of resectable and borderline-resectable pancreatic head...
Durable Responses Observed With Novel Oncolytic Therapy in Recurrent Glioma
IN A PILOT study of recurrent glioma, 26% of patients treated with the optimal dose of vocimagene amiretroprepvec (aka Toca 511), a novel oncolytic virus therapy, achieved durable, long-term responses and remained alive 3 or more years later. This outcome far exceeded “historical benchmarks” for...
Expert Point of View: Sarah Blair, MD
SARAH BLAIR, MD, a breast surgeon at the University of California San Diego, noted that lymphedema remains a significant clinical problem, although the rates of lymphedema are decreasing, as fewer full axillary node dissections are performed. “This study utilizes bioimpedance spectroscopy, a...
Early Detection and Intervention Reduce Breast Cancer–Related Lymphedema
A NEW STUDY has found that early detection along with a simple intervention can be highly effective in preventing breast cancer–related lymphedema for at-risk women. According to data presented at the 2018 Annual Meeting of the American Society of Breast Surgeons,1 82% of women identified at an...
Expert Point of View: Judy C. Boughey, MD
JUDY C. BOUGHEY, MD, a breast surgeon and clinical and translational researcher at the Mayo Clinic, Rochester, Minnesota, said the two studies highlight the importance of discussing genetic testing with patients who are diagnosed with breast cancer. “With the advances in panel testing for...
